Patrick Conway, MD, explains why CMS looked toward value-based insurance design for Medicare Advantage plans.
Patrick Conway, MD, says that CMS is looking towards value-based insurance design for Medicare Advantage plans.
Transcript (modified)
What is it about value-based insurance design that CMS thought would make it a good fit for a Medicare Advantage Demonstration?
So we had seen value-based insurance design in the private market, we’d seen some evidence of its potential to improve quality, to lower cost, and to increase delivery of high-value services. And we’re hearing from Medicare Advantage (MA) Plans that they wanted the ability to have value-based insurance design in the MA program.
So we put forward that model where, in the process of getting applications and selecting those applications, we think incentivizing the consumer, the beneficiary, to seek out high-value services will be beneficial to Medicare Advantage plans and to our health system.
Joanne Mizell: Lifestyle Modification Programs Take Holistic Aim at Metabolic Disease
May 1st 2024Joanne Mizell shares insurer strategies in addressing the escalating rates of metabolic diseases, highlighting the importance of holistic treatment methods like lifestyle modification programs, which integrate nutrition, physical activity, and community engagement.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
OptumRx’s Jon Mahrt Discusses “Irresponsible” Drug Pricing for Products With Multiple Indications
April 30th 2024When the same product comes to market with additional indications, irrational pricing decisions result in ever increasing prices instead of volume translating to lower costs, said Jon Mahrt, MBA, of OptumRX.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Makers of medical tests will have about 4 years to show the FDA that their new offerings deliver accurate results; after previously decreasing for 27 years, US tuberculosis (TB) cases increased every year since 2020; a US district judge rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to the Medicare drug price negotiation program.
Read More